A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
Status:
Recruiting
Trial end date:
2024-05-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of
belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants
with impaired hepatic function and in matched RRMM participants with normal hepatic function.